NASDAQ · BNR
Burning Rock Biotech Limited financials
$18.94+7.43%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $77.1M | $70.7M | $75.9M | $81.7M | $80.4M | $66.8M |
| Gross profit | $57.6M | $49.6M | $51.3M | $55.1M | $57.8M | $49.0M |
| Gross margin | 74.7% | 70.3% | 67.6% | 67.5% | 71.9% | 73.4% |
| Operating income | -$7.8M | -$49.0M | -$94.6M | -$142.1M | -$124.9M | -$62.4M |
| Net income | -$7.9M | -$47.5M | -$92.3M | -$140.8M | -$125.3M | -$54.1M |
| Net margin | −10.3% | −67.2% | −121.6% | −172.4% | −155.8% | −80.9% |
| Diluted EPS | $-0.07 | $-0.46 | $-0.90 | $-1.36 | $-12.04 | $-10.50 |
| EBITDA | -$4.7M | -$37.0M | -$75.7M | -$124.1M | -$117.3M | -$57.3M |
| Operating cash flow | -$4.1M | -$12.6M | -$36.1M | -$66.2M | -$75.2M | -$11.3M |
| Free cash flow | -$4.8M | -$13.4M | -$37.3M | -$76.4M | -$108.4M | -$22.9M |
| Diluted shares | 106.3M | 102.9M | 102.4M | 103.9M | 10.4M | 5.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.4M | $71.2M | $86.9M | $131.3M | $224.6M | $290.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $10.0M | $55.5M |
| Total debt | $271.6K | $0.00 | $0.00 | $0.00 | $372.0K | $7.2M |
| Total assets | $117.3M | $121.3M | $146.9M | $230.1M | $357.6M | $408.1M |
| Total liabilities | $40.8M | $41.7M | $38.4M | $62.2M | $68.0M | $37.1M |
| Shareholders' equity | $76.5M | $79.6M | $108.6M | $167.9M | $289.6M | $371.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology